Published in
American Society of Hematology, Blood, 17(130), p. 1903-1910, 2017
DOI: 10.1182/blood-2017-04-779736
Links
Tools
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Journal article published in 2017 by
Christian W. Eskelund,
Christina Dahl,
Jakob W. Hansen,
Maj Westman,
Arne Kolstad,
Lone B. Pedersen,
Carmen P. Montano-Almendras,
Simon Husby,
Catja Freiburghaus,
Sara Ek,
Anja Pedersen,
Carsten Niemann 
,
Riikka Räty,
Peter Brown ,
Christian H. Geisler
and other authors.
,
Riikka Räty,
Peter Brown ,
Christian H. Geisler
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points The intensified standard-of-care regimens for younger patients with MCL do not overcome the deleterious effects of TP53 mutations. MCLs with TP53 mutations should be considered for alternative frontline treatment.